Enveric Biosciences reports positive IND‑enabling ADMET results for EB‑003
Enveric Biosciences announced that its IND‑enabling in‑vitro ADMET studies for the non‑hallucinogenic candidate EB‑003 produced favorable results. The program evaluated the molecule in more than 70 assays, showing strong intestinal absorption, low plasma protein binding and stability against liver metabolism enzymes. CEO Joseph Tucker said the data support continued advancement toward a planned first‑in‑human trial. The news coincided with a 6.25% pre‑market decline in ENVB shares to $1.35.
Why it matters
The milestone strengthens the company’s preclinical profile, but the lack of a disclosed IND filing timeline leaves short‑term regulatory uncertainty. The share price drop reflects market reaction to the news.
Key facts
- 1Enveric reported positive IND‑enabling ADMET results for EB‑003. tradingview.com
- 2The IND‑enabling studies examined the compound in over 70 individual assays. finance.yahoo.com
- 3EB‑003 showed strong intestinal absorption potential in human cell permeability tests. finance.yahoo.com
- 4EB‑003 exhibited low plasma protein binding in vitro. finance.yahoo.com
- 5The molecule was stable against human and animal liver metabolism enzymes. finance.yahoo.com
- 6EB‑003 did not significantly inhibit or induce major metabolic enzymes or multidrug transporters. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.